Back to Search Start Over

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Authors :
Borlenghi, Erika
Masina, Lorenzo
Frigeni, Marco
Lotesoriere, Ivana
Molteni, Alfredo
Fumagalli, Monica
Riva, Marta
Zappasodi, Patrizia
Bernardi, Massimo
Fracchiolla, Nicola
Gigli, Federica
Basilico, Claudia
Pagani, Chiara
Lussana, Federico
Perfetti, Paola
Cattaneo, Chiara
Tajana, Monica
Viola, Silvia
Martini, Gianluca
Catalano, Gloria
Sciumè, Mariarita
Condorelli, Annalisa
Cela, Giselda
Rossi, Giuseppe
Tucci, Alessandra
Cairoli, Roberto
Todisco, Elisabetta
Source :
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p956-956, 1p
Publication Year :
2023

Abstract

Introduction:In elderly acute myeloid leukemia (AML) patients (pts) the debate about the use of intensive chemotherapy (iC) as opposed to non-intensive therapy (niT) or best supportive care (BSC) is a hot topic, particularly after the introduction of venetoclax (VEN) use. Age, comorbidities, functional impairment, therapy benefits and risks, pts preferences, and AML features influence this choice. The SIE/SIES/GITMO (“fitness”) criteria (Ferrara, 2013) are a valuable and comprehensive tool, but a revalidation is needed in the light of the new treatment options.

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
142
Issue :
1, Number 1 Supplement 1
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs64699819
Full Text :
https://doi.org/10.1182/blood-2023-180568